Compare J & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | J | INSM |
|---|---|---|
| Founded | 1947 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | J | INSM |
|---|---|---|
| Price | $135.62 | $197.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $155.90 | ★ $180.94 |
| AVG Volume (30 Days) | 1.4M | ★ 2.8M |
| Earning Date | 11-20-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $12,029,783,000.00 | $447,022,000.00 |
| Revenue This Year | N/A | $43.10 |
| Revenue Next Year | $6.38 | $128.25 |
| P/E Ratio | $56.94 | ★ N/A |
| Revenue Growth | 4.60 | ★ 30.34 |
| 52 Week Low | $106.23 | $60.40 |
| 52 Week High | $168.44 | $212.75 |
| Indicator | J | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 51.97 |
| Support Level | $132.50 | $189.59 |
| Resistance Level | $143.16 | $206.69 |
| Average True Range (ATR) | 3.29 | 6.40 |
| MACD | 0.47 | -2.76 |
| Stochastic Oscillator | 41.82 | 30.20 |
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.